Senior Vice President, Head of Global Clinical Development, EMD Serono, Inc.
Alise Reicin, MD, is Senior Vice President and Head of Global Clinical Development in R&D at Merck Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany.
Reicin leads the Global Clinical Development organization, including the Clinical Development Therapeutic Areas; Evidence Value and Development; Biostatistics; Clinical Operations; and both the Japan and China R&D Hubs. In this capacity, she also leads Merck Serono’s portfolio of pipeline programs.
Prior to joining Merck Serono, Reicin served as Vice President, Project and Pipeline Leadership, Oncology Franchise at MSD (Merck, Sharp & Dohme). She led MSD’s PD-1 program and oversaw the initial development and filing activities worldwide, including the first approval in the US. She also managed program leaders across early and late oncology product development teams.
Before joining MSD, Reicin was a faculty member at Columbia Medical School, and a physician and researcher at Columbia Presbyterian Hospital.
Reicin has a degree in biochemistry from Barnard College of Columbia University. She received her Medical Degree from Harvard Medical School, where she was enrolled in the Health Sciences and Technology program with MIT (Massachusetts Institute of Technology).
In her role as Head of Global Clinical Development at Merck Serono, Reicin reports to the head of Global R&D and serves as a member of the R&D Executive Leadership Team.